Who we are
We see a future where sequencing generates more information from DNA and is achievable at far lower costs, bringing closer the day when advanced medicines, diagnostics and personalized treatments become a reality for all.
Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.
Our Team
Leadership
Gail Marcus
Chair of the Board
Professor Sir Shankar Balasubramanian FRS
Founder
Dr. Joanna Holbrook
Senior Vice President of Research
Fiona Stewart
Chief Financial Officer
Dr. Philippa Burns
Director of Research & Development
Dr. Páidí Creed
Director of AI, Bioinformatics and Software
Manuela Morgan
Head of Human Resources
Scientific Advisors
Professor Sir Shankar Balasubramanian FRS
Founder
Professor Wolf Reik
Head of the Epigenetics Programme, Babraham Institute
Professor Anjana Rao
Head of the Division of Signalling and Gene Expression, La Jolla Institute
Professor Mark Dawson
Group Leader of the Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre
Rahul Kohli
Associate Professor of Medicine and Biochemistry & Biophysics, Penn Epigenetics Institute, University of Pennsylvania (UPenn)
Board
Gail Marcus
Acting CEO
Dr. Bobby Yerramilli-Rao
Co-Founder
Professor Sir Shankar Balasubramanian FRS
Founder
Tom Hulme
General Partner, GV
Alice Newcombe-Ellis
Managing Partner, Ahren Innovation Capital
Somu Subramaniam
Managing Partner, New Science Ventures
Roelof F. Botha
Managing Partner, Sequoia Capital
Investors
Ahren
Syncona
GV
New Science Ventures
Sequoia Capital